CD274 and diffuse large B-cell lymphoma: In addition, not only the administration of immunotherapeutic agents, but also immune editing that allows CAR‐T cells to ignore the inhibitory signals from PD‐L1 or LAG‐3 can also open new avenues for DLBCL immunotherapy.